Elevated serum levels of Wisteria floribunda agglutinin‐positive human Mac‐2 binding protein predict the development of hepatocellular carcinoma in hepatitis C patients
Top Cited Papers
Open Access
- 12 July 2014
- journal article
- viral hepatitis
- Published by Ovid Technologies (Wolters Kluwer Health) in Hepatology
- Vol. 60 (5), 1563-1570
- https://doi.org/10.1002/hep.27305
Abstract
The Wisteria floribunda agglutinin‐positive human Mac‐2‐binding protein (WFA+‐M2BP) was recently shown to be a liver fibrosis glycobiomarker with a unique fibrosis‐related glycoalteration. We evaluated the ability of WFA+‐M2BP to predict the development of hepatocellular carcinoma (HCC) in patients who were infected with the hepatitis C virus (HCV). A total of 707 patients who had been admitted to our hospital with chronic HCV infection without other potential risk factors were evaluated to determine the ability of WFA+‐M2BP to predict the development of HCC; factors evaluated included age, sex, viral load, genotypes, fibrosis stage, aspartate and alanine aminotransferase levels, bilirubin, albumin, platelet count, alpha‐fetoprotein (AFP), WFA+‐M2BP, and the response to interferon (IFN) therapy. Serum WFA+‐M2BP levels were significantly increased according to the progression of liver fibrosis stage (P < 0.001). In each distinctive stage of fibrosis (F0‐F1, F2, F3, and F4), the risk of development of HCC was increased according to the elevation of WFA+‐M2BP. Multivariate analysis identified age >57 years, F4, AFP >20 ng/mL, WFA+‐M2BP ≥4, and WFA+‐M2BP 1‐4 as well as the response to IFN (no therapy vs. sustained virological response) as independent risk factors for the development of HCC. The time‐dependent areas under the receiver operating characteristic curve demonstrated that the WFA+‐M2BP assay predicted the development of HCC with higher diagnostic accuracy than AFP. Conclusion: WFA+‐M2BP can be applied as a useful surrogate marker for the risk of HCC development, in addition to liver biopsy. (Hepatology 2014;60:1563–1570)This publication has 49 references indexed in Scilit:
- A serum “sweet-doughnut” protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitisScientific Reports, 2013
- Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: A multicenter prospective study (the FIBROSTIC study)Journal of Hepatology, 2010
- Alpha-fetoprotein above normal levels as a risk factor for the development of hepatocellular carcinoma in patients infected with hepatitis C virusThe Esophagus, 2010
- Clinical significance of elevated alpha‐fetoprotein in Alaskan Native patients with chronic hepatitis CJournal of Viral Hepatitis, 2007
- Prediction model of hepatocarcinogenesis for patients with hepatitis C virus-related cirrhosis. Validation with internal and external cohortsJournal of Hepatology, 2006
- Sampling variability of liver fibrosis in chronic hepatitis CHepatology, 2003
- The role of liver biopsy in chronic hepatitis CHepatology, 2002
- Role of liver biopsy in management of chronic hepatitis C: A systematic reviewHepatology, 2002
- Elevated serum levels of 90K/MAC-2 BP predict unresponsiveness to α-interferon therapy in chronic HCV hepatitis patientsJournal of Hepatology, 1996
- Prospective study of α-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinomaHepatology, 1994